Clinical Trials

Study Title:
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

For more information about the trial above please contact the study team:

Principal Investigator, Jacqueline Kraveka, at kravekjm@musc.edu.

Study Coordinator, Jake Rodriguez, at rodrijos@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina